Form 4: Karyopharm Therapeutics Director Zhen Su Acquires 4,600 Stock Options
Insider Transaction Report
Karyopharm Therapeutics Inc. Director Zhen Su has acquired 4,600 nonstatutory stock options with an exercise price of $4.48, which will fully vest on May 28, 2026.
Summary
- Zhen Su, a Director of Karyopharm Therapeutics Inc. (KPTI), acquired 4,600 nonstatutory stock options on May 28, 2025.
- The options have an exercise price of $4.48 per share.
- These options are set to vest 100% on May 28, 2026.
- The options expire on May 27, 2035.
- The reported amounts reflect a one-for-fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.
Sentiment
Score: 7
Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns their interests with shareholders and suggests confidence in the company's future, though it is a routine compensation event rather than a major operational announcement.
Positives
- The acquisition of stock options by a director aligns their interests with those of shareholders, potentially indicating confidence in the company's future performance.
Future Outlook
The vesting schedule indicates that the director's full beneficial ownership of these options will materialize on May 28, 2026, aligning their long-term incentives with the company's performance.
Industry Context
This transaction represents a standard form of equity compensation for directors in the biotechnology and pharmaceutical industry, aiming to incentivize long-term commitment and align management interests with shareholder value.
Related Party Transactions
- The grant of stock options to a director is a related party transaction, representing a form of compensation from the company to an insider.
Stakeholder Impact
- Shareholders: The grant of options to a director can be seen as a positive signal, aligning the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
Next Steps
- The options will vest on May 28, 2026, at which point the director will have the right to exercise them.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Effective date of the one-for-fifteen reverse stock split. |
| 05/28/2025 | Date of the stock option grant (earliest transaction date). |
| 05/29/2025 | Date the Form 4 filing was signed. |
| 05/28/2026 | Date when 100% of the acquired stock options will vest. |
| 05/27/2035 | Expiration date of the nonstatutory stock options. |
Keywords
Karyopharm Therapeutics, KPTI, Zhen Su, stock options, insider transaction, Form 4, beneficial ownership, director, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.